Mitchell de Long
Corporate Officer/Principal bei AERIE PHARMACEUTICALS, INC.
Profil
Mitchell A.
de Long is currently working as the Vice President-Chemistry at Aerie Pharmaceuticals, Inc. He previously worked as a Research Scientist at Procter & Gamble Co. Dr. de Long holds a doctorate degree from Stanford University.
Aktive Positionen von Mitchell de Long
| Unternehmen | Position | Beginn |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2005 |
Ehemalige bekannte Positionen von Mitchell de Long
| Unternehmen | Position | Ende |
|---|---|---|
| PROCTER & GAMBLE COMPANY | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mitchell de Long
| Stanford University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| Private Unternehmen | 1 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
